Recombinant Human TNFRSF18 Protein, MYC/DDK-tagged

• Cat.No.: TNFRSF18-1995H
• Product Overview: Recombinant human TNFRSF18 protein, fused to MYC/DDK-tagged at C-terminus, was expressed in HEK293

Specification

• Description: Receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. Mediated NF-kappa-B activation via the TRAF2/NIK pathway. [UniProtKB/Swiss-Prot Function]
• Source: HEK293
• Species: Human
• Tag: Myc&DDK
• Form: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.
• Molecular Mass: 23.5 kDa
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Concentration: >50 ug/mL as determined by microplate BCA method

Gene Information

• Gene Name: TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Homo sapiens ]
• Official Symbol: TNFRSF18
• Synonyms: AITR; CD357; GITR; GITR-D
• Gene ID: 8784
• mRNA Refseq: NM_004195
• Protein Refseq: NP_004186
• MIM: 603905
• UniProt ID: Q9Y5U5

Reviews

12/20/2021

This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

03/05/2020

Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

10/01/2017

The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

Q&As

What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment?

Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

Are there any approved TNFRSF18-targeted therapies for cancer treatment?

As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

Are there potential side effects associated with TNFRSF18-targeted therapies?

Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

How can TNFRSF18-targeted therapies potentially improve cancer outcomes?

TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

Can TNFRSF18-targeted therapies be used in combination with other immunotherapies?

Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.